Dilon Technologies acquires assets of Dune Medical including MarginProbe

Dilon Technologies Inc. acquired substantially all assets of Dune Medical, including the MarginProbe device for breast cancer surgery. The deal was announced on April 2, 2020.

“Dilon Technologies Inc., a world class global leader in breast cancer treatment and diagnosis and owner of the Navigator Gamma Probes has acquired substantially all the assets of Dune Medical, including Marginprobe's 'MarginProbe'.”dilon.com

• 1 source
• dilon.comDilon Technologies® Inc. acquires the DuneMedical’s MarginProbeTM - Dilon TechnologiesDAY VisionApr 3, 2020

Summarized from public sources; check the original articles before acting on it.